The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Abstract
Inhibiting a specific isoform of TGFβ augments the effectiveness of checkpoint blockade therapy in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent results in fact highlight the role of increased TGF-β signaling in intrinsic resistance to checkpoint blockade therapy21,23,38,71,145.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
In the citing paper
“Finally, an antibody was developed that binds the TGF-β1 prosegment and prevents dissociation of mature TGF-β1 from LAP, thus keeping TGF-β1 latent without affecting TGF-β2 or TGF-β3 activation71.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
In the citing paper
“However, in contrast to treatment with the TβRI kinase inhibitor LY2109761 or a pan-TGF-β antibody, antibody-mediated repression of TGF-β1 activation did not result in cardiac valvulopathies in a rat toxicity model71.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
In the citing paper
“An underlying and predominant rationale focuses on the ability of TGF-β released and activated by cancer cells, stromal fibroblasts and/or immune cells to dampen anti-tumor immunity and responses to immunotherapeutics through direct and indirect mechanisms21,23,71,145,353,354.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
In the citing paper
“treatments that combine TGF-β inhibition with immune checkpoint inhibition are likely to increase therapeutic efficacy21,23,71,145,346,362.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
In the citing paper
“Considering that TGF-β, CTLA-4 and PD-L1/PD-1 signaling act as parallel immunosuppressive pathways that repress cytotoxic T cell, NK cell and macrophage activities through distinct mechanisms”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [71]
Citations
Cites
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The EMBL-EBI search and sequence analysis tools APIs in 2019
Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Cited by
Sorted by citations
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Immunotherapy: Reshape the Tumor Immune Microenvironment
Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
Metadata
- Authors
- Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., Streich, F. C., Boston, C., Simpson, A., Jackson, J. W., Lin, S., Danek, N., Faucette, R. R., Raman, P., Capili, A. D., Buckler, A., Carven, G. J., & Schürpf, T.
- Affiliations
- Scholar Rock (United States) (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Martin, Constance J.
- Datta, Abhishek
- Schürpf, Thomas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-03-25
- Volume
- 12
- Issue
- 536
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3013319043
- Cited by
- 224
- References
- 68
- Citations by year
- 2026: 13 · 2025: 32 · 2024: 40 · 2023: 28 · 2022: 49 · 2021: 41 · 2020: 21
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, tumor immune microenvironment, T cells, immunosuppressive myeloid cells, cardiac valvulopathy
- MeSH terms
- Animals, Humans, Neoplasms, Signal Transduction, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Rats, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
